MedTrace Logo

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

NCT03093831 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-10-11

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Ibrutinib in predominantly Asian patients with relapsed or refractory marginal zone lymphoma.

Conditions

  • Lymphoma, B-Cell, Marginal Zone

Interventions

DRUG

Ibrutinib

560mg administered orally once daily.

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Tiffany PL Tang · National Cancer Centre, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-08
Primary Completion
2020-07-17
Completion
2020-07-17

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03093831 on ClinicalTrials.gov